Sabrina Serani

Following clearance from the FDA, a phase 1/2 study will assess OBI-902 in Trop-2-overexpressing solid tumors, with plans for enrollment to begin later this year.

Updated findings from a phase 2 study investigating the IL-2–binding monoclonal antibody AU-007 show a manageable safety profile with strong antitumor evidence.

Reduced-dose radiotherapy in head & neck cancer shows similar efficacy to standard dose but with lower toxicity, per findings from the UPGRADE-RT trial.

Antibody-drug conjugates continue to show benefits in breast cancer, plus the FDA has fast-tracked an innovative AI tool to help identify pancreatic tumors.

Enfortumab vedotin plus pembrolizumab followed by surgery showed high complete response rates in advanced urothelial cancer.

With the clearance of an investigational new drug application from the FDA, a phase 1/2a study will evaluate VS-7375 in KRAS G12D-mutant solid tumors.

Ivonescimab plus chemotherapy improved survival in advanced squamous NSCLC vs tislelizumab and chemotherapy in a phase 3 trial.

FDA designates BCB-276 as a breakthrough therapy for pediatric DIPG, offering hope for improved treatment of this challenging brain tumor.

The DESTINY-Breast09 trial showed that first-line fam-trastuzumab deruxtecan plus pertuzumab improved progression-free survival in HER2+ metastatic breast cancer.

The week marked several FDA approvals for drugs and devices, plus data continues to show tarlatamab’s benefit in small cell lung cancer.

The DAMO PANDA can accurately detect pancreatic cancer lesions, and FDA breakthrough therapy designation aims to accelerate its development and approval.

Bexmarilimab and azacitidine showed continued tolerability and a high overall response rate in relapsed/refractory higher-risk myelodysplastic syndromes in a phase 2 study.

The FDA granted regenerative medicine advanced therapy designation to iltamciocel for patients with oropharyngeal dysphagia following head and neck cancer treatment.

The first patient in a phase 2 clinical trial evaluating 67Cu-SAR-bisPSMA for patients with metastatic castration-resistant prostate cancer has been dosed.

The approval of this combination is supported by data from the phase 3 CodeBreaK 300 study.

Acalabrutinib with bendamustine and rituximab is now an FDA-approved treatment for patients with previously untreated mantle cell lymphoma.

This approval marks the first and only approved subcutaneously administered PD-1 inhibitor.

Saro H. Armenian, DO, MPH, discussed the unique challenges facing children diagnosed with cancer and their families and what lies on the horizon.

Joseph Greer, PhD, discussed a study evaluating in-person vs telehealth modalities of early integrated palliative care for patients with advanced lung cancer.

Following a complete response letter and biologics license application resubmission, the FDA has approved remestemcel-L for the treatment of pediatric patients with steroid-refractory acute graft-vs-host disease.

The approval of durvalumab, based on data from the phase 3 ADRIATIC study, offers a new standard of care for patients with limited-stage small cell lung cancer.

With this approval, zenocutuzumab is the first FDA-approved therapy for patients with NRG1 fusion tumors.

The bispecific antibody zanidatamab is now the first HER2-targeted therapy approved for patients with locally advanced or metastatic HER2-positive biliary tract cancer.

Combining the checkpoint inhibitor atezolizumab with targeted therapy led to improvements in overall survival in patients with anaplastic thyroid cancer.

Sunvozertinib has shown promising results in patients with non–small cell lung cancer with an EGFR exon 20 insertion mutation.

Bevacizumab in combination with atezolizumab and chemotherapy led to improvements in progression-free survival and duration of response in patients with advanced biliary tract cancer.

The study is evaluating AJ1-11095, a novel agent for the treatment of myelofibrosis that did not respond to or relapsed following treatment with a type I JAK2 inhibitor.

Three phase 3 trials of combinations including datopotamab deruxtecan for the treatment of non–small cell lung cancer are beginning.

The FDA recently approved the combination of inavolisib, fulvestrant, and palbociclib in this patient population.

Barbara O’Brien, MD, discussed findings and implications from the phase 2 TBCRC049 study evaluating the combination of tucatinib, trastuzumab, and capecitabine in HER2-positive breast cancer with leptomeningeal metastasis.